Warning Letters Are Not New Rules: FDA Enforcement vs Rulemaking on Peptides
Regulatory · 17 September 2026
Five FDA warning letters to peptide sellers were posted on 1 September 2026, and a great deal of commentary since has described them as a change in the rules. They are not. A warning letter is an enforcement action against one named company under law that already exists. Changing what is or is not lawful for everyone else is a separate, slower process called rulemaking — and on the peptide questions, that process has not moved since July.
What the FDA warning letters to peptide sellers actually said
The five letters are all dated 24 August 2026 and were posted to FDA’s public warning letter database on 1 September. They were issued by the Center for Drug Evaluation and Research and signed by Tina Smith, M.S., Captain, U.S. Public Health Service, Director of the Office of Unapproved Drugs and Labeling Compliance. In each case FDA states that it reviewed the firm’s website in July 2026.
The recipients, named here only as the factual addressees of public federal documents, were Peak Performance Peptides (reference 735127), Peptide Partners LLC (735063), Royal Peptides LLC (734884), NuScience Peptides LLC (733652) and TXP Innovations LLC dba Tex Peptides (735067).
The legal charge in each is the same: that the products offered are unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act, because the website’s own copy established an intended use within the meaning of section 201(g)(1). The single most instructive passage, quoted here from the Peak Performance letter, is the footnote addressing the site’s disclaimer:
“Despite statements on your product labeling marketing your products for ‘research use only’ and ‘not for human consumption,’ evidence obtained from your website establishes that your products are intended to be drugs for human use.”
That is the holding worth understanding. A disclaimer is a statement by the seller; intended use is a conclusion FDA draws from the evidence, including the rest of the website. The label does not settle the question on its own.
An accuracy note on the word “misbranded.” FDA’s database index lists these letters under the subject line “Unapproved New Drugs/Misbranded,” and much of the secondary coverage has repeated that framing. We checked the letter body: it contains no misbranding section, no discussion of section 502, and does not use the word. The only violation heading is Unapproved New Drug Violations. The misbranding label exists in FDA’s indexing taxonomy, not in the letters themselves.
What a warning letter is — and is not
A warning letter is an allegation and a request for corrective action. Recipients are given fifteen working days to respond describing what they have done to correct the violations. It is not a court judgment, not a finding of liability, not a fine and not a ban. Firms can and do respond, contest, or change their websites.
Crucially, it binds nobody else. A warning letter to one company creates no new obligation for any other company, and it does not alter the legal status of any substance. It is the application of existing law to a specific set of facts.
What rulemaking is, and why it is slower
Changing the rules runs through a different sequence. For the 503A bulk drug substances list, a substance is nominated, the Pharmacy Compounding Advisory Committee may be asked for advice, FDA publishes a proposed rule, a public comment period runs, and only then can a final rule issue. Each step is a matter of public record and each takes months.
The step people most often mistake for a decision is the advisory committee vote. PCAC advises; it does not decide. Its recommendations carry weight but no legal force, and nothing becomes compoundable because a committee voted for it. We covered the July vote and what it did and did not settle in our report on the 503A recommendations.
Where the peptide rules actually stand
Three federal items are open, and none of them moved in the first half of September.
On the 503A bulks list, PCAC met on 23–24 July 2026 and recommended six of seven peptides considered. FDA has not published a proposed rule, so the comment period and final rule both remain ahead. On the 503B bulks list, FDA proposed on 30 April 2026 to exclude semaglutide, tirzepatide and liraglutide; the comment period closed on 30 July 2026 and no final determination has been announced. A second PCAC peptide meeting is expected by the end of February 2027 but still has no announced date, location or Federal Register docket — see our note on that meeting.
Why the two get conflated
Enforcement is visible and dated; rulemaking is quiet and slow. Five letters landing on one day reads like a turning point, while a proposed rule that has not appeared generates no headlines at all. The result is a predictable pattern: a burst of enforcement gets reported as though the legal landscape shifted, when what actually happened is that existing law was applied to five specific websites.
The practical reading, for anyone following this area: watch the Federal Register for the proposed rule, not the warning letter database, if the question you care about is what the rules are.
Frequently asked questions
Do these warning letters make research-use-only labelling illegal?
No. The letters do not outlaw any form of words. They state that in these specific cases the disclaimer did not determine the products’ intended use, because FDA drew a different conclusion from the evidence on the rest of the website. That is a fact-specific determination about five firms, not a rule about labelling language.
Is a warning letter the same as a recall or a ban?
No. A warning letter alleges violations and asks for correction within fifteen working days. Recalls, seizures, injunctions and prosecutions are separate actions that may or may not follow. Many warning letters are resolved by the firm making changes.
Did the July PCAC vote make six peptides legal to compound?
No. PCAC is an advisory committee. Its vote is a recommendation to FDA. Inclusion on the 503A bulks list requires a proposed rule, a comment period and a final rule, none of which has happened.
How would I check the current status myself?
Enforcement actions appear in FDA’s warning letter database, searchable by company and date. Rulemaking appears in the Federal Register and on FDA’s advisory committee pages. Both are free and authoritative, and they are the sources this article is built from.
References
- FDA. Warning letter to Peak Performance Peptides, reference 735127, 24 August 2026. fda.gov
- FDA. Warning letter to Peptide Partners LLC, reference 735063, 24 August 2026. fda.gov
- FDA. Warning letter to Royal Peptides LLC, reference 734884, 24 August 2026. fda.gov
- FDA. Warning Letters database. fda.gov
- FDA. July 23–24, 2026 meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- FDA. FDA proposes to exclude semaglutide, tirzepatide and liraglutide on the 503B bulks list. fda.gov
Informational only — not medical advice and not legal advice. This article summarises public federal documents and does not recommend, endorse or comment on any seller or product. Consult a qualified professional for advice on your own situation. Intended for readers 21 and over.
